Navigation Links
Buchang Global Health Forum 2009: An Innovative Approach for Management of H1N1 Swine Flu
Date:12/3/2009

NEW YORK, Dec. 3 /PRNewswire/ -- According to the World Health Organization, the human H1N1/09 Type A influenza ("Swine Flu") has reached a pandemic level. Over 500,000 cases have been confirmed worldwide with at least 6,500 fatalities. Since there is no longer a requirement to test and report individual cases, these numbers undoubtedly understate the real situation.

(Photo: http://www.newscom.com/cgi-bin/prnh/20091203/NY20654 )

There are currently only two approved drugs ("Oseltamivir" and "Zanamivir") based on evidence that both worked for the seasonal influenza A. The vaccine for H1N1/09 Type A has just been clinically tested and is now available to the public, however drug-resistant strains of the virus have emerged recently in Norway, Hong Kong and the USA.

Buchang USA Inc. together with the Chinese Cultural Foundation and Greater China Corporation co-organized the first Buchang Health Forum - 2009 in New York City to focus on this global health emergency. The primary goal of the Buchang Health Forum was to provide an integrative "East-meets-West" platform for healthcare experts and patient advocacy groups to exchange their views and knowledge on the management of this and other global pandemics.

During a panel discussion at the Buchang Forum, David Jin, M.D., Ph.D. of Cornell University introduced the concept of integrative medicine and how to optimize prevention and treatment strategies for the H1N1 infection. Dr. Jin stated that: "This global pandemic can only be managed and controlled through international collaboration of medical, pharmaceutical, and educational resources."

Dr. Yang Xu, a prominent Traditional Chinese Medicine ("TCM") doctor as well as President of Buchang USA, brought some exciting news from China. Dr. Xu reported that: "The Ministry of Health in China recently screened thousands of TCM herbal regimens and studied their effectiveness against human H1N1/09 Type A influenza virus as well as their capability to boost our immune system...The official results are now available to the public in China...One product, 'Xiangju' which contains 8 different herbal ingredients stood out above all others." Since its approval by the State FDA (China) as an OTC product for the relief of flu and cold-like symptoms, Xiangju has become one of the most effective and popular herbal regimens in China with no noticeable side-effects. The recent recommendation of Xiangju by the Ministry of Health has provided an evidence-based option for combating the H1N1 Swine Flu, which could potentially save millions of lives worldwide. Buchang is proud to have developed Xiangju as a way to help alleviate this global health problem.

Buchang USA is the North American subsidiary of the Buchang Group with headquarters in Xi'an, China. It is one of the ten largest pharmaceutical companies in China with an outstanding reputation for stringent quality control and product safety. Buchang's TCM products are currently available in China, the US, Singapore, Indonesia, Thailand, Hong Kong, Russia and other countries. Buchang USA will continue to support healthcare education programs and integrative medicine with its annual Buchang Health Forums. Please contact: buchangusa@gmail.com, or call (917) 930-8118 for more information about Buchang's products and future events.

SOURCE Buchang USA


'/>"/>
SOURCE Buchang USA
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Corbett Selected to Host the Only Midwest Global Awards Judging Competition
2. Tata Consultancy Services to Support Roches Global Capacity Building Initiative
3. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
4. Briefing on a new Web resource to address global drinking water crisis
5. MDS Pharma Services Wins Award for Management of Global Malaria Trial
6. Neusoft Becomes First Global Growth Company Partner of World Economic Forum
7. Resonant Medical Appoints New Vice President of Global Sales
8. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
9. The era of global aging: GSAs annual meeting to present new research on hot topics in aging
10. MEDEX Global Group & Harvard Medical International Join Forces to Create the Most Comprehensive Health Information Resource for International Travelers
11. Ultrasonix Adds Global Medical Imaging Into Its North American Sales Force
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... ... “The Trials I Face to Receive God’s Grace”: a mesmerizing take on one ... better one’s life through God. “The Trials I Face to Receive God’s Grace” is ... found a love for writing. Green feels that expressing his feelings through prayer will ...
(Date:9/20/2017)... ... 2017 , ... Houston, Texas, investment firm CORDA Investment Management, LLC, believes in ... 11, off work and rolled up their sleeves to help with relief efforts. The ... start the process of rebuilding. , CORDA founder Bonner C. Barnes notes that investment ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures of a young ... creation of published author, Jeanine Liston, a busy mother of five who used her time ... been writing this book for over twenty years. It was a way to give ...
(Date:9/20/2017)... ... September 20, 2017 , ... “Monique”: is the story of Monique, whose ... creation of published author, Colleen Crispi, has owned four beauty salons and written a ... in real estate and cooking. , “The doctor’s office was only three blocks ...
(Date:9/19/2017)... NY (PRWEB) , ... September 19, 2017 , ... ... announced today the addition of strategic marketing leader, Denise Flannery, to its strategic ... Marketing, Brand and Management Consultant, Denise will work with clients across different industries ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
(Date:9/5/2017)...  Just 18 months after its February 2016 launch, ... the appointment of three new senior people to its ... Jones-Phillips and James Wright bring decades ... Tammy Wynne joins as Director, ... She has over ten years, experience in global market ...
(Date:8/31/2017)... PM360,s annual Innovations Issue, published in ... innovations happening across the industry. Established six years ago, ... providing a comprehensive look at the newest and most ... innovative companies, startups, divisions, products, services, and strategies from ... "Everyone in this industry wants to do better—in all ...
Breaking Medicine Technology: